Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (130 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: placebosubjectdoublem2kg
  Phrases that lowered it: participantspatientsaccordingeffect ofarm
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 2 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.6% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 14.9% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome NCT02394119 · started 2015 · scored riskier than 46% of active trials completed
• Rituximab for Idiopathic Nephrotic Syndrome NCT04494438 · started 2013 · scored riskier than 50% of active trials completed
• IL-2 for Multi Drug Resistant Nephrotic Syndrome NCT02455908 · started 2012 · scored riskier than 54% of active trials completed
• Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome NCT02438982 · started 2015 · scored riskier than 50% of active trials completed
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) NCT02592798 · started 2016 · scored riskier than 59% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.